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Introduction: Smoking prevalence remains high in some vulnerable groups, 
including those who misuse substances, have a mental illness, are homeless or are 
involved with the criminal justice system. E-cigarette use is increasing and may 
support smoking cessation/reduction. 
Methods: Systematic review of quantitative and qualitative data on the effectiveness 
of e-cigarettes for smoking cessation/reduction among vulnerable groups. Databases 
searched were MEDLINE, EMBASE, PsychINFO, CINAHL, ASSIA, ProQuest 
Dissertations and Theses and Open Grey. Narrative synthesis of quantitative data 
and thematic synthesis of qualitative data. 
Results: 2628 records and 46 full texts were screened; 9 studies were identified for 
inclusion. Due to low quality of evidence, it is uncertain whether e-cigarettes are 
effective for smoking cessation in vulnerable populations. A moderate quality study 
suggested e-cigarettes were as effective as nicotine replacement therapy. Four 
studies suggested significant smoking reduction, however three were uncontrolled 
and had sample sizes below 30. A prospective cohort study found no differences 
between e-cigarette users and non-users. No significant adverse events and minimal 
side effects were identified. Qualitative thematic synthesis revealed barriers and 
facilitators associated with each component of the COM-B (capability, opportunity, 
motivation, behaviour) model, including practical barriers; perceptions of 
effectiveness for cessation/reduction; design features contributing to automatic and 
reflective motivation; smoking bans facilitating practical opportunity; and social 
connectedness increasing social opportunity.  
Conclusion: Further research is needed to identify the most appropriate device 
types for practicality and safety, level of support required in e-cigarette interventions, 
and to compare e-cigarettes with current best practice smoking cessation support 
among vulnerable groups. 
IMPLICATIONS 
Smoking prevalence among people with mental illness, substance misuse, 
homelessness or criminal justice system involvement remains high. E-cigarettes 
could support cessation. This systematic review found limited quantitative evidence 
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assessing effectiveness. No serious adverse events were identified. Qualitative 
thematic synthesis revealed barriers and facilitators mapping to each component of 
the COM-B (capability, opportunity, motivation, behaviour) model, including practical 
barriers; perceived effectiveness; design features contributing to automatic and 
reflective motivation; smoking bans facilitating practical opportunity; and social 
connectedness increasing social opportunity. Further research should consider 
appropriate devices for practicality and safety, concurrent support, and comparison 
with best practice smoking cessation support. 
 
INTRODUCTION 
Smoking prevalence remains high among some vulnerable groups, including those 
who misuse substances, have a mental illness, are homeless or are involved with 
the criminal justice system (CJS) (1). Prevalence is estimated at 88% among 
substance misusers (2), 77% among people who are homeless (3), 74% in prisons 
(4), 33% among people with mental illness (5), and 75% in serious mental illness 
(SMI) (6).  
Attributable morbidity and mortality is considerable. Mortality among substance 
misusers who concurrently smoked was four times higher than non-smokers (7) and 
tobacco-related causes were the leading cause of death among people receiving 
inpatient substance misuse treatment (8). People with SMI or homelessness have 
significantly reduced life expectancy, to which high smoking prevalence contributes 
considerably (9-12). Wilcox estimates more prisoners in the United States of 
America (USA) die from second hand smoke than are legally executed (13).   
Key barriers to smoking cessation among vulnerable groups remain. Among those 
with mental illness and/or substance misuse, perceptions that smoking is beneficial 
for managing symptoms, part of daily routine, culture and identity, and provides 
social connectedness are key barriers (14, 15). 
Electronic cigarette (e-cigarette) use has grown rapidly, and may support smoking 
cessation, but there is little evidence on long term effects. A Cochrane review 
identified two RCTs suggesting e-cigarettes are more effective for long term smoking 
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cessation compared with placebo e-cigarettes and one RCT found no significant 
differences between e-cigarettes and nicotine patch (16). However, overall evidence 
was considered of ‘low’ or ‘very low’ quality due to low event rates and wide 
confidence intervals. No serious adverse events were identified but long term safety 
data was lacking. Qualitative research in the general population suggests e-
cigarettes are able to attain to all the aspects of smoking considered important, being 
pleasurable, replacing habitual aspects and providing social connectedness (17).   
Estimated e-cigarette use prevalence among tobacco smokers in the United 
Kingdom (UK) is 21.9%, and 36.5% report ‘ever use’ (18). In the USA 15.9% report 
current use and  47.6% ever use (19). USA estimates suggest current use among 
smokers in community mental health treatment is 22% (20) and ever use among 
acute psychiatric admissions 11% and increasing (21). Ever and current use among 
substance misusers are 73% and 33.8% respectively (22). Past month e-cigarette 
use was estimated as 12-51% among homeless tobacco smokers (23-25). No CJS 
data was available. Reasons for e-cigarette use include smoking 
cessation/reduction, (22-28) curiosity/experimentation, (22, 24, 28) use where 
smoking is banned, (23, 24, 26-28) lower cost (24-26) and harm reduction (24-27).   
E-cigarettes are regulated differently from smoking cessation therapies in many 
countries, and consequently funded differently, e.g. in the UK, unlike nicotine 
replacement therapy (NRT), bupropion and varenicline, e-cigarettes are not available 
on prescription and users must buy them. For vulnerable groups with potentially 
limited income, including the homeless, those in inpatient services and prison 
populations, cost may be a barrier. In view of the difference in funding mechanisms 
between e-cigarettes and other methods of smoking cessation support in many 
countries, health economics outcomes, such as economic impact of the adoption of 
e-cigarettes among vulnerable groups compared with other options for smoking 
cessation/reduction, are of interest. 
In settings where smoking is banned e-cigarettes are often included without 
consideration of potential benefits. ‘Smoke-free’ homeless shelters, psychiatric 
hospitals and prisons are common and increasing. The UK National Institute for 
Health and Care Excellence (NICE) currently do not recommend e-cigarettes (29), 
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whilst a Public Health England (PHE) evidence update suggests smokers who have 
struggled to quit, or do not wish to, should be encouraged to switch to e-cigarettes as 
they are around 95% safer, but highlight that continued vigilance and further 
research is needed (30). To date, there has been no systematic review of the 
effectiveness of e-cigarettes for vulnerable groups.  
This report aims to (i) systematically review evidence for the effectiveness of e-
cigarettes for smoking cessation and reduction among these vulnerable groups; and 
(ii) identify barriers and facilitators to e-cigarette use.  
The protocol was registered on PROSPERO (31). Review questions were: 
 Are e-cigarettes effective and cost-effective for smoking cessation or 
reduction for vulnerable groups? 
 Are any adverse events associated with e-cigarette use in vulnerable 
groups? 
 What are the barriers and facilitators to e-cigarette use for vulnerable 
groups? 
 
METHODS 
 
A systematic review of quantitative and qualitative literature on the effectiveness of 
e-cigarettes for smoking cessation and reduction among vulnerable groups, and 
barriers and facilitators to e-cigarette use, was conducted.  
 
Inclusion criteria 
 
Study design 
 
A range of designs were included as scoping searches suggested limited available 
controlled evidence. The following study designs were eligible:  
 
 For assessing effectiveness: randomised controlled trials (RCTs), cluster 
randomised controlled trials (cRCTs), quasi-RCTs, controlled before and after 
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studies (CBA), interrupted time series (ITS), cohort studies, case-control 
studies and uncontrolled before and after studies (uBA).  
 For assessing quantitative data on barriers and facilitators to e-cigarette use: 
longitudinal, cross-sectional or cohort surveys. 
 For assessing qualitative data on barriers and facilitators to e-cigarette use: 
qualitative studies with any recognised method of data collection (e.g. 
interviews, focus groups) and analysis from any discipline or theoretical 
tradition (e.g. grounded theory, thematic analysis).  
 
Participants 
 
Participants and carers’ of any age in any country/setting in at least one of the 
following vulnerable groups:    
 
 Mental illness: Anyone diagnosed with a condition in the International 
Classification of Diseases and Related Health Problems 10 (ICD-10) 
classification of Mental and Behavioural Disorders (32) or the Diagnositc and 
Statistical Manual of Mental Disorders (DSM-5) (33) and/or who was an 
inpatient or outpatient in a mental health treatment/rehabilitation centre. 
Those with transient psychiatric symptoms (e.g. self-reported depressive 
symptoms but no diagnosis/treatment for depressive disorder) were excluded 
as they were felt to face different challenges for smoking cessation e.g. time 
spent in a treatment facility and medication interactions.  
 Substance misuse: People in treatment/recovery for any form of substance 
misuse including illegal and prescribed drugs, legal highs and alcohol. ‘In 
treatment’ included inpatient and outpatient substance misuse treatment. 
Participants were considered in ‘recovery’ if they met the UK Drugs Policy 
Definition of ‘voluntarily sustained control over substance use which 
maximises health and wellbeing and participation in the rights, roles and 
responsibilities of society’ (34). Medication assisted recovery, such as 
methadone programmes, were included, as well as abstinence-based 
programmes. Focus was on treatment/recovery rather than casual substance 
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misuse, as they were thought to face different challenges for smoking 
cessation e.g. time spent in a treatment facility.  
 Homeless: Individuals meeting national criteria for homelessness in the 
country/countries where the study was conducted or those accessing services 
for the homeless (35). In the UK, legally a person is homeless if they have no 
accomodation they are entitled to occupy, or the accomodation they are 
entitled to occupy is in such poor condition they cannot be reasonably 
expected to occupy it (36).   
 Criminal justice system (CJS): Those detained at any stage, including police 
custody, people on remand/convicted and detained in any prison 
type/category and those on probation.  
These four vulnerable groups, and not others, were chosen because they have 
particularly high smoking prevalence, suggesting smoking has not been de-
normalised among these groups, and because there is some overlap between the 
groups, for example prevalence of mental illness and/or substance misuse is high 
among the homeless (37) and people involved with the CJS (38). 
  
Interventions 
 
Studies investigating e-cigarettes, defined as ‘electronic devices that heat a liquid 
into an aerosol for inhalation. The liquid usually comprises propylene glycol and 
glycerol, with or without nicotine and flavours, and stored in disposable or refillable 
cartridges or a res rvoir’ (16). Disposable, non-rechargeable e-cigarettes, 
rechargeable e-cigarettes with replaceable pre-filled cartridges, and rechargeable e-
cigarettes with a refillable tank reservoir into which ‘e-liquid’ is added were included 
(39). ‘Heat not burn’ products, in which heated tobacco is vaporised, were excluded 
(40).  
 
Comparison group 
 
 E-cigarette versus another type of nicotine or non-nicotine e-cigarette; 
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 E-cigarette versus smoking cessation intervention (e.g. NRT, behavioural 
intervention); 
 E-cigarette versus no or delayed intervention.  
 
Uncontrolled before and after studies were included if baseline measurements were 
reported. Weaknesses of such designs are considered in quality assessment below.   
 
Outcome measures 
 
Studies reporting on any of the primary or secondary outcomes were included.  
Primary outcomes 
 
 Smoking cessation at longest follow-up, by any measure, self-report and 
preferably expired-air carbon monoxide (eCO) verified and in accordance 
with the Russell Standards (41). 
 Serious or non-serious adverse events. Adverse event was defined as 
‘any undesirable experience’ associated with use (42). It was considered 
serious if it led to death, threatened life, hospitalisation (initial or 
prolonged), permanent damage/disability, congenital anomaly, required 
intervention to prevent permanent impairment/damage, or other important 
medical events which may jeopardise the patient and/or require 
medical/surgical intervention. Of particular interest were interactions with 
prescribed psychiatric medications, fires caused by e-cigarette chargers or 
self-harm associated with e-liquid. 
 Perceived barriers and facilitators to e-cigarette use.  
 
Secondary outcomes 
 
 Smoking reduction, assessed by self-report and preferably confirmed 
biochemically, at longest follow up; 
 Retention in a smoking cessation, substance misuse, mental health or 
other treatment programme.  
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 Health economics outcomes.  
 
 
 
 
Database searches 
 
Following searches from similar systematic reviews (15, 16, 35) a strategy was developed in 
MEDLINE using MeSH and free text terms (Box 1), tested against a sample of relevant 
papers and adapted for other databases.  
 
Searches were from 2004, when modern e-cigarettes became available (16) to 
March 2017. Reference lists of included studies and systematic reviews were 
screened. Searches were not restricted by language but studies without a full text 
available in English would have been excluded, although none relevant were 
identified. Articles not referring to any included vulnerable group(s) or to e-cigarettes 
by any recognisable name, in the title/abstract, were excluded. 
 
 
Data extraction 
 
Search results were merged using Endnote and de-duplicated. Titles and abstracts 
were screened according to pre-specified inclusion/exclusion criteria by one author 
(SG) with 10% double screened by a second (CN). There were two discrepancies, 
which were resolved by discussion. Potentially included full text articles were 
retrieved and reviewed and 10% double screened, with no discrepancies. Data were 
extracted using a standardised data extraction sheet by SG and a sample (four 
studies) double checked by CN, with no discrepancies. Double screening and data 
extraction of only a sample was necessary due to resource limitations, and has been 
done in similar reviews (15, 43, 44).  
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RCTs/cRCTs would have been appraised using the Cochrane risk of bias tool (45), 
although none were identified. Other quantitative studies were assessed using the 
Effective Public Health Practice Project (EPHPP) criteria (46), and qualitative studies 
using the Critical Appraisal Skills Programme (CASP) checklist (47), by SG, and a 
sample (four studies) double checked by CN with no discrepancies. Results were 
used to inform narrative synthesis (48). 
 
Data synthesis 
 
Due to heterogeneity of design, participants, interventions and outcomes suggested 
by scoping searches, narrative synthesis of quantitative data was planned from the 
protocol stage, based on guidance by Popay et al. (48-50). A thematic analysis of 
reported qualitative data was conducted (51, 52). Data were entered into Excel to 
assist with coding. ‘First-level’ codes aimed to summarise the meaning of the text or 
capture authors’ original language. Coding was identified as original data or author 
interpretation. Synthesis involved organisation of first level codes into second level 
descriptive themes, summarising first level codes whilst remaining close to the 
included studies. Third level analytical themes were then developed. This stage 
involved ‘going beyond’ or ‘interpreting’ the first and second level codes to capture 
the line of argument (53) and generate new findings from pooled data.  
To explore relationships in the data, themes emerging from qualitative data were 
mapped onto the COM-B model, a ‘behaviour system’ within which capability, 
motivation and opportunity interact to generate behaviour, which also influences 
each of these omponents (54). Capability includes both practical and psychological 
components, motivation includes automatic and reflective processes, and 
opportunity includes physical aspects, such as physical accessibility, and social 
aspects, such as community or family support. The model has been applied to 
tobacco control (54) and general population e-cigarette use (55) but not as part of a 
systematic review on e-cigarette use among vulnerable groups. Application of the 
COM-B model was considered appropriate for this systematic review because 
relating data to the conditions which this established theory assumes must be met 
for behaviour to change, which are likely different for vulnerable groups compared 
Quality assessment 
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with the general population, may provide insights into how to facilitate switching from 
combustible tobacco to e-cigarettes.  
 
 
 
RESULTS 
 
The PRISMA Flow Diagram (56) reports records identified, duplicates, records 
screened and included/excluded, full text articles assessed and studies included in 
narrative synthesis (Figure 1).  
 
Study characteristics  
 
Searches revealed 9 studies meeting the inclusion criteria. Five quantitative studies 
were included (total participants n=1089). Of the included quantitative interventional 
studies (total participants n=133), there was one secondary analysis (57) of an RCT 
(58), and three uncontrolled before and after studies (6, 59-61) (one study was 
reported in both a conference abstract (61) and a full article (59)). One cohort 
observational study was included (n=956) (21). Four qualitative studies were 
included (62-65); three involving focus groups (n=128) (63-65) and one qualitative 
analysis of online postings (62). Five studies were performed in the USA (6, 21, 60, 
63, 64) and one in each of Australia (65), Italy (59, 61), New Zealand (57) and 
international posters online (62).   
 
Participants 
 
Six studies included participants with mental illness (6, 21, 57, 59, 61, 62, 65), two 
homelessness (63, 64), and one substance misusers (60). No studies involving the 
CJS were identified. Attrition was minimal.   
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Mental illness populations were heterogeneous and included people reporting being 
prescribed one or more psychiatric medications (57), SMI diagnosis (6), 
schizophrenia (59, 61) and acute psychiatric admissions (21). Self-report psychiatric 
medication use is likely less accurate for case ascertainment than ICD-10/DSM-IV 
criteria. Qualitative studies included community mental health clients (65) and 
posters discussing e-cigarettes in the context of mental illness online (62).  
Two qualitative and no quantitative studies involving homeless populations were 
identified. One recruited from homeless shelters (63). The second included 
homeless parents living in family shelters (64).    
Only one quantitative study (60) and no qualitative studies focussed on substance 
misusers. The study involved people on methadone and may not be representative 
of users of other substances. Number of participants included in each study are 
reported in Table 1. Participant characteristics of quantitative and qualitative studies 
are detailed in Supplementary Tables 1 and 2 respectively. 
 
Interventions and comparisons 
  
Four intervention studies were identified (6, 57, 59, 60). The main intervention focus 
was free provision of e-cigarettes, suggesting researchers may have considered cost 
a barrier. Only one study included behavioural support (low intensity voluntary 
telephone counselling) (57). One study offered e-cigarette use instructions plus 
telephone technical and medical assistance (59). The remaining studies provided 
only instructions for use (6, 60). No explicit theoretical basis for interventions were 
described. One study emphasised collecting ‘real-life’ data hence no encouragement 
or motivational support was provided (59). All suggested e-cigarettes may be 
considered a harm reduction strategy (6, 57, 59, 60). See Supplementary Table 3 for 
further intervention details.  
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Five studies addressed smoking cessation (6, 21, 57, 59, 60), four adverse events 
(6, 57, 59, 60), five smoking reduction (6, 21, 57, 59, 60) and four reported 
qualitative data on barriers and facilitators to e-cigarette use (62-65). 
 
 
 
 
Quality assessment 
 
Four of the included quantitative studies were rated globally as weak (6, 21, 59, 60) 
using the EPHPP criteria (46), and one was rated moderate (57). Included qualitative 
studies were of moderate quality, with global scores calculated based on the CASP 
checklist ranging from 6-8 out of ten. Further details on the scores for each criteria 
are available in Supplementary Tables 4 and 5.  
 
Primary outcomes 
Smoking cessation  
 
Four interventional studies assessed smoking cessation outcomes among those 
receiving an e-cigarette intervention (6, 57, 59, 60). Smoking cessation varied from 
0.0% (60) - 14.3% (59) (details of how each study defined smoking cessation are 
provided in Table 1). Three studies included people with mental illness (6, 57, 59) 
and one, people on methadone (60). Three studies were rated as weak on quality 
appraisal and included fewer than 30 participants, making statistical analyses 
potentially unreliable (6, 59, 60). The fourth was rated moderate and was the only 
study with a control group (57). There were no significant differences between 
nicotine e-cigarette, non-nicotine e-cigarette and NRT, however this secondary 
analysis of an RCT had limited power. None of the included studies met all parts of 
the Russell Standards. Two studies partially met them. O’Brien et al. assessed 
Outcomes 
Downloaded from https://academic.oup.com/ntr/advance-article-abstract/doi/10.1093/ntr/nty054/4955785
by University of East Anglia user
on 04 April 2018
Ac
ce
pte
d M
an
us
cri
pt
 
 
 
biochemically verified continuous abstinence at 6 months (57) and Caponetto et al. 
assessed 52-week complete self-reported and CO verified abstinence (not even a 
puff) for 30 days before assessment (59).  
One observational study involving people with mental illness found no significant 
difference between e-cigarette users and non-users (21) (Table 1). Participants were 
part of an RCT comparing brief, extended and usual smoking cessation treatment, 
so may not be representative of wider mental illness populations. 
 
Adverse events 
 
No serious adverse events were reported (6, 57, 59, 60). Some side effects were 
reported, commonly cough, headache and throat irritation. O’Brien et al. compared 
adverse events/month among e-cigarette users with and without mental illness and 
found no significant difference (0.05 events/month in both groups (p=0.592, IRR 
0.89, 95% CI 0.59-1.35)) (57). Adverse event counts were similar between nicotine 
e-cigarette, placebo e-cigarette and NRT but small numbers prohibited significance 
testing. Caponetto et al. reported side effects experienced among people with mental 
illness resolved over time (59), but no data beyond 52 weeks were available. For 
further detail see Supplementary Table 6.      
 
Barriers and facilitators 
 
Four moderate quality qualitative studies reporting data relating to these outcomes 
(62-65) were thematically synthesised and mapped to the COM-B model (Figure 2). 
How qualitative data link to each aspect of the framework is discussed below, with 
barriers and then facilitators presented, with illustrative quotes. Supplementary Table 
7 details which themes arose from which studies. 
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Physical capability 
Physically accessing, safely operating and maintaining supplies to use an e-cigarette 
was a barrier (62, 65): 
“I think you would have to be organised and organise your finances and make 
sure that when it does run out you’ve got something to fill it up with, because 
that would be the time when you go, “Oh bugger I’ve run out of this” and you 
would go and buy a packet of cigarettes or whatever.” (65) 
Concerns were raised about safely refilling, charging, and cleaning. Potential danger 
of ‘e-liquid’ for those at risk of self-harm was concerning (62, 63, 65): 
“I think what the OP [original poster] means is that nicotine on its own is more 
poisonous than cyanide and arsenic. 60 mg will kill a light smoker, and I 
believe 45 mg is enough to kill many people who don’t smoke. Giving nicotine 
juice to someone with major depressive disorder may not be the best idea in 
the world.” (62) 
Assistance from family/carers and design (e.g. closed cartridges) were suggested 
solutions (62): 
“My mother has schizophrenia . . . She has a terrible smokers cough and I 
think if I could get her to swap to e-cigarettes it would make a hell of a 
difference . . . Trouble is it needs to be dead simple. Even the recharging 
could cause problems and the refilling almost certainly would have to be done 
periodically by members of the family . . . Good charge and easy to charge. 
Maybe affordable enough to have a few so she can wait for a family member 
to refill or very easy to refill.” (62) 
Psychological capability 
E-cigarettes were considered less harmful than cigarettes and were an alternative 
source of nicotine for cessation (62-65) and reduction (62, 63, 65):  
“I quit through vaping, not just a little tiny one but it’s good to invest on 
something expensive. Although you’re trading one addiction for another, it’s 
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the lesser of the two evils. I was a pack a day smoker and I quit within two 
weeks.” (62) 
“yeah an e-cigarette really helped me to quit smoking. Like even when I was 
pregnant and trying to quit smoking I used a patch, like the doctors prescribed 
me a patch to quit smoking and that didn't even work as well as the e-
cigarette did.” (63) 
Physical opportunity 
Some spent more money personalising e-cigarette/vaping equipment than they 
previously did on cigarettes, whilst others found them cheaper (62, 65). Balancing 
personalisation with affordability was considered necessary: 
 “Let’s not talk about money. I’ve fallen deep into the rabbit hole. Turn away 
and save yourselves, but it’s too late for me. Cigarette money is now going on 
vape gear. Anyway . . . ” (62) 
“The mods and juices are so cheap that it is like it is non-existent to my 
budget. I don’t have to skip on dates like when I was taking concerta.” (62) 
E-cigarette use where smoking is banned was a facilitator (62, 63): 
“I’m a frequent flier at “Happy Camp.” That’s how my family and I jokingly refer 
to the mental health floor at the hospital. Regular as clockwork, I think life is 
out of control every five years or so. The last time, 2009, we were still allowed 
to go outside (up on the roof LOL) twice a day to smoke. I’m guessing that 
won’t be the case next year when I’m ready for an emotional oil change. I’ve 
definitely got to get to vaping full time by then. I don’t know that they will allow 
vaping, but I figure it is a much better bet than smoking.” (62)    
Social opportunity 
Reversal of the de-normalisation of smoking was feared (63):    
"I remember when…a couple of years back they used to have this commercial 
for Newports and it'd be like a dude…a DJ…a black dude. You know and I 
even had something to say about like when they started the Blu [e-
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cigarette]…I was like oh my god, they're allowing smoking on TV because you 
don't really see that too often. I don't remember seeing a commercial 
promoting smoking, so it was like advertising directed to me, but the whole 
Newport thing, that was a whole culture, you know like this is what you do, 
you're cool, you're high, you're drinking and by the way, have a Newport.” (63) 
Family/friends, healthcare professionals and online posters facilitated e-cigarette 
initiation and provided moral and practical support. E-cigarettes were socially 
acceptable and provided a community of ‘vapers’ with opportunities for interaction 
and connectedness (62): 
“Have a renewed sense of self-worth and no longer feel like a second class 
citizen because I have a nicotine addiction that makes me a social pariah 
because of the smell and stigma attached to analogue cigarettes. Thank you 
so much to the/r/electronic_cigarette community for acting as a catalyst to 
such a positive change in my life!!!” (62) 
Automatic motivation 
Physical side effects (e.g. sore throat) were a barrier (62, 65): 
“I found a problem with them and I tried them for a while and I get a bit of 
asthma and I found with the vapour it would make my lungs rattle a bit, so I 
would worry that long term you might get pleurisy or something from taking in 
the moisture, a bit of fluid on the lungs.” (65) 
Visible vapour provided an experience similar to smoking which NRT cannot offer. 
Views on device appearance and flavour were mixed (62, 63, 65): 
“It doesn’t look like a cigarette should, would not make me want to smoke it.” 
(65) 
[Referring to inhaler, in contrast to EC] “No good [ . . . ] because the vapour 
you see the smoke coming out and you’re drawing on something, the vapour 
is going to work.” (65) 
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Concerns about continued or worsening habit/addiction were barriers (62, 63, 65): 
“I went through it faster than I probably would have a pack of cigarettes and 
then also my brother enlightened me, he was like e-cigarettes they say they're 
supposed to be better for you because it's vapor this and that, but really it's 
not because it gives you the opportunity to smoke cigarettes in places where 
you can't smoke. So you're smoking that and you're in an environment where 
it's not smoking, but the e-cigarette is allowed, but technically yeah you're not 
harming anybody else, but you're still smoking...you're still harming yourself, 
so you're smoking more than you normally would smoke.” (63) 
E-cigarettes were perceived to have both beneficial and negative effects on 
psychiatric symptoms and medication side effects (62, 65): 
“I have PTSD, anxiety symptoms from that, and TBI-related memory issues 
and micro seizures. For me, vaping is pretty much the same as smoking, in 
terms of how it helps me calm down and handle stress.” (62) 
“Vaping doesn’t really do it for me. That’s due to there being chemicals in 
burnt tobacco that function very similar to antidepressants (which is one of the 
big things that makes tobacco addicting). vaping doesn’t have those, and thus 
only has the effects of nicotine, which aren’t as strong.” (62) 
E-cigarettes were more desirable than NRT (62-65): 
“Of the cessation tools discussed, participants were much more interested in 
e-cigarettes or replacing smoking with an alternative habit than they were in 
using either patches or medication..” (64) [Author interpretation]  
Ability to take charge of nicotine addiction was empowering (62), facilitated by ability 
to choose and personalise the device (62, 65): 
“Now this kit was pretty good, I barely felt the nicotine, but I started to feel 
confident, and felt a lot of my anxiety drift away. I’ve been starting to regain 
control of my life; hell I’m even posting on reddit. Vaping not only saved my 
life, but freed me from a cage.”(62) 
 Reflective motivation 
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“The thing is they’re not trying to look like a cigarette. They are clearly 
something different. You can personalise them and they come in different 
colours. You can get some that are a bit quirky. They treat you like an adult 
with something you might want.” (65) 
Some considered e-cigarettes an alternative habit to smoking. It was a hobby 
associated with a community of ‘vapers’, both valued distractions from other life 
challenges (e.g. mental illness) (62, 65): 
 “Vaping works for my anxiety because I’m a fidgeter and a comfort eater. I 
need something to do with my hands, and often that something is to put things 
in my mouth. Vaping satisfies both of those comfort mechanisms. I can get 
the same effect with a Rubik’s Cube and a lollipop, except I’m diabetic so the 
lollipop is a terrible idea.” (62) 
“OK, here’s from someone who also suffers social anxiety, vaping has helped 
in more ways than quitting smoking. It’s a conversation starter. People will 
approach you. People will want to know what you’re doing. At first it’s 
overwhelming but over time it’s helped build my confidence in extreme ways.” 
(62) 
 
Secondary outcomes 
 
Smoking reduction 
 
Five studies reported on smoking reduction (6, 21, 57, 59, 60). A moderate quality 
study of people on medication for mental illness suggested a reduction of 9.9 
cigarettes/day among 16mg nicotine e-cigarette users compared with 5.7 among 
patch users (Table 2) (57). This difference was statistically significant and, if 
sustained, may lead to clinically significant differences, but the study lasted only 26 
weeks and included only 86 participants. There was some evidence from three weak 
quality uncontrolled before and after studies of statistically significant smoking 
reduction from baseline to follow up for participants with mental illness (6, 59) and 
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substance misuse (60). Reduction was confirmed with eCO among those with 
mental illness. However, as there was no control group, it is unclear if these 
reductions would have occurred without e-cigarettes. An observational study found 
no significant reduction in smoking among e-cigarette users (21).   
 
 
Other treatment and health economics outcomes 
 
No studies reported on treatment retention or health economics. 
 
 
 
 
 
DISCUSSION 
 
The primary objective of this systematic review was to assess effectiveness of e-
cigarettes for smoking cessation among vulnerable groups. Due to low quality of 
available evidence, whether e-cigarettes are effective remains uncertain. There was 
some evidence from a moderate quality study that e-cigarettes were as effective as 
NRT for smoking cessation. There was some evidence from four studies of 
statistically and clinically significant smoking reduction, however, three were 
uncontrolled and had sample sizes less than 30. There were no differences between 
e-cigarette users and non-users in a prospective cohort study, although there were 
limitations in case ascertainment (participants asked about “all forms of tobacco 
use”) and as participants were recruited from an RCT of smoking cessation 
interventions, those who had already stopped/reduced smoking using e-cigarettes 
may not have participated (16).  
Villanti et al. propose methodological criteria for determining whether a study 
provides sufficient information to establish whether e-cigarettes facilitate smoking 
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cessation/reduction: 1) examines outcome of interest; 2) assesses e-cigarette use 
for cessation as exposure of interest; 3) employs appropriate control/comparison; 4) 
ensures measurement of exposure preceded outcome; 5) evaluates dose and 
exposure duration; and 6) evaluates type and quality of device (66). All the included 
quantitative studies assessed cigarette abstinence. Only two studies assessed e-
cigarette use for cessation as the exposure of interest (57, 60). Only one study 
included an appropriate control group (57). The four interventional studies ensured 
exposure preceded outcome (6, 57, 59, 60). None evaluated dose, exposure 
duration or device quality. None of the included studies met all parts of the Russell 
Standards. Two studies partially met them. O’Brien et al. assessed biochemically 
verified continuous abstinence at 6 months (57) and Caponetto et al. assessed 52-
week complete self-reported and CO verified abstinence (not even a puff) for 30 
days before assessment (59). 
Qualitative thematic synthesis revealed barriers and facilitators mapping to each 
component of the COM-B model, and suggests e-cigarettes have the potential to be 
able to attain to key aspects of smoking addiction, being pleasurable, replacing 
habitual aspects, providing an alternative identity as a ‘vaper’ and facilitating social 
connectedness through a vaping community. It also suggests vulnerable groups may 
require additional support to enable e-cigarette use, in terms of choosing a device, 
using it safely, access to e-cigarettes and accessing the social connectedness 
‘vaping’ can provide.   
No serious adverse events were reported. Qualitative studies highlighted concerns 
about e-liquid access for those at risk of self-harm, which case reports show has 
been used in intentional overdose (67). Future studies should consider how design 
adaptations could improve safety.  
Included interventions provided minimal support alongside e-cigarettes. This is 
similar to studies of e-cigarette interventions among the general population (16), but 
in contrast to combined behavioural support and NRT offered by English stop 
smoking services (68). Triangulation with qualitative data highlights importance of e-
cigarettes as an empowering way of providing control over nicotine addiction. Further 
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research is needed to establish whether e-cigarettes are effective alone or with 
support.  
Strengths and limitations of the evidence base 
 
Three of the five included quantitative studies had sample sizes of less than 30. 
Some studies included only self-report smoking reduction, risking recall bias. Neither 
the uncontrolled before and after studies nor the cohort study adjusted for 
confounders. Failure to adjust for confounders, including level of nicotine 
dependence, in cohort studies of NRT led to underestimation of effectiveness (16, 
69).   
Overall quantitative evidence was weak. Qualitative evidence was moderate. Much 
available qualitative data was from a single study analysing online posts about e-
cigarettes for those with mental illness. Those who are motivated to post online are 
more likely to have strong views, reducing transferability. However, such methods 
obtained rich data from participants using a self-initiated innovative nicotine delivery 
device.    
Heterogeneity of included studies in terms of participants, interventions, comparisons 
and outcomes reduced comparability and prohibited meta-analysis. All included 
studies were from high income countries, thus generalisability to other settings is 
limited, and publication bias is a possibility.  
No data were found on the CJS. E-cigarettes are a consumer product that entered 
and have proliferated in the market largely outside the health arena, in contrast to 
medicinally licensed products (e.g. NRT) (17). This may be why little data is available 
for the CJS, where access to such consumer products is restricted. As more prisons 
become smoke-free, with some recognising the potential role of e-cigarettes in 
supporting smoking abstinence, this evidence gap may begin to be filled.  
No data were available on health economics outcomes. Further research is needed 
into how e-cigarettes, if effective for smoking cessation/reduction, could best be 
funded for vulnerable groups.  
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None of the included studies discussed ‘vaping’ other substances (e.g. cannabis), 
which may be of concern (30), particularly among substance misusers.  
 
Strengths and limitations of this review 
 
Strengths include the comprehensive search strategy, triangulation of quantitative 
and qualitative data, application of behaviour change theory and focus on 
underserved populations.  
The scope of this review specified four vulnerable groups (people with mental illness, 
substance misuse, homelessness or CJS involvement), but other groups may also 
be considered vulnerable, including young people, pregnant women, lower 
socioeconomic groups and indigenous populations (35), and the effect of e-
cigarettes on these groups should be considered in future studies.  
That it was only feasible to independently double screen 10% of citations is a 
limitation. Richness of qualitative synthesis was restricted by the limitations of 
available data. Triangulation of qualitative and quantitative data and application of 
the qualitative data to a recognise  theory of behaviour change has attempted to 
make the most of extremely limited available data.  
 
Implications 
 
This review highlights the need for further research into the role of e-cigarettes for 
vulnerable groups and the challenge of making recommendations for public health 
policy.  
The available evidence assessing effectiveness of e-cigarettes for smoking 
cessation for vulnerable groups was limited. No serious adverse events were 
identified, and side effects were minimal. In view of the harm caused by tobacco, 
recommendations from PHE that e-cigarettes be considered for those who have 
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been unable to stop smoking (30) appears appropriate for vulnerable groups as well 
as the general population.  
Qualitative data highlighted concerns about e-cigarettes reversing de-normalisation 
of smoking (63). However, tobacco is arguably yet to be de-normalised among these 
groups (35). Consideration of the differences in harm between e-cigarettes and 
tobacco is needed before including the former in smoking bans. PHE report 
negligible levels of nicotine in ambient air and no health risks for bystanders have 
been identified (30). The South London and Maudsley NHS Foundation Trust, an 
English mental health trust, implemented a ‘smoke-free’ policy including guidance 
supporting e-cigarette use in bedrooms and grounds for patients who have tried 
other cessation methods (70).     
No cost-effectiveness studies were identified. Unlike NRT, e-cigarettes are 
unlicensed and not available on prescription, thus users pay for them (30). ‘Starter 
kits’ including battery, charger and replaceable nicotine cartridges cost £17-90 (71).   
 
Future directions 
 
Pilot studies comparing different intervention designs for usability and safety for 
vulnerable groups would be beneficial. Adequately powered RCTs comparing e-
cigarettes with best practice smoking cessation support are needed. Comparison of 
e-cigarette interventions with and without associated support would help to identify 
how they may be used effectively. Qualitative process evaluations alongside trials 
could elucidate method of action and acceptability. Cost-effectiveness studies are 
required. No studies were found involving the CJS. With moves towards banning 
smoking in UK prisons (72) and elsewhere (73) such research is needed. Future 
studies should also consider the role e-cigarettes could play in smoking relapse 
prevention for vulnerable groups.  
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Due to the low quality of available evidence it is uncertain whether e-cigarettes are 
effective for smoking cessation for vulnerable groups. However, included studies 
identified no serious adverse events and qualitative studies suggested e-cigarettes 
could attain to key aspects of smoking addiction, including habit and social 
connectedness. In view of the harm tobacco causes, PHE recommendations that e-
cigarettes be considered for those unable to stop smoking appear appropriate for 
vulnerable groups as well as the general population. Further research is needed to 
identify the most appropriate type of device, level of support required and to compare 
e-cigarettes with best practice smoking cessation support among vulnerable groups.  
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Box 1. Search strategy as used in MEDLINE 
 
Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and 
Ovid MEDLINE(R) 1946 to Present 
 
1 e-cig$.mp           
2 electr$ cigar$.mp          
3 electronic nicotine.mp         
4 (vape or vaper or vapers or vaping).ti,ab.       
5 1 OR 2 OR 3 OR 4          
6 Exp Mental Health Services/         
7 Exp Mental disorders/         
8 Mentally ill persons/         
9 Mental health /         
10 (mental health OR suicide OR depression OR anxiety OR emotional distress OR 
psychological distress OR schizophrenia OR bipolar OR manic depression).ti,ab.   
11 6 OR 7 OR 8 OR 9 OR 10         
12 Substance-Related Disorders/        
13 exp Alcohol-Related Disorders/        
14 Amphetamine-Related Disorders/        
15 Cocaine-Related Disorders/        
16 Inhalant Abuse/          
17 Marijuana Abuse/          
18 exp Opioid-Related Disorders/         
19 Phencyclidine Abuse/          
20 Substance Abuse, Intravenous/        
21 exp Alcohol Drinking/          
22 Marijuana Smoking/         
23 Methadone/           
24 exp Substance Abuse Treatment Centers/       
25 12 OR 13 OR 14 OR 15 OR 16 OR 17 OR 18 OR 19 OR 20 OR 21 OR 22 OR 23 or 24  
26 exp Homeless Persons/         
27 exp Housing/          
28 Homeless*.ti,ab.         
29 26 OR 27 OR 28         
30 Prisons/          
31 Prisoners/          
32 (Prison* OR crime* OR criminal* OR detain* OR detention).ti,ab.     
33 (correctional facility OR correction centre OR correctional health service* OR jail).ti,ab.  
34 Juvenile delinquency/         
35 (juvenile delinquency OR juvenile behavior).ti,ab.      
36 30 OR 31 OR 32 OR 33 OR 34 OR 35       
37 Vulnerable populations/        
38 11 OR 25 OR 29 OR 36 OR 37         
39 5 AND 38           
40 limit 39 to humans          
41 limit 40 to yr=”2004 –Current”  
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Table 1. Summary of quantitative findings for smoking cessation 
RCT SECONDARY ANALYSIS         
Study ID Outcome Total participants  Method of outcome assessment Time of 
follow up 
Intervention 
group 1 n/N (%) 
Intervention 
group 2 n/N 
(%) 
Control 
group n/N 
(%) 
Significance test Quality of evidence 
(EPHPP)  
  
O’Brien 2015 Biochemically 
verified 
continuous 
Abstinence 
86 Continuous smoking abstinence six 
months after quit day, verified by an 
exhaled breath carbon monoxide 
measurement of <10 ppm using a 
Bedfont Micro Smokerlyzer. 
26 weeks 
 
2/39 (5.1%) 
 
0/12 (0.0%) 5/35 (14.3%) 0.245 (patch vs. 16 
mg e-cig) 
- (16 mg vs. 0 mg e-
cig) 
0.115 (patch vs. 
combined e-cig) 
Moderate 
UNCONTROLLED BEFORE AND AFTER STUDIES       
Study ID Outcome Total participants 
(retained at last 
follow up) 
Method of outcome assessment Time of 
follow up 
Intervention 
group 1 n/N (%) 
Intervention 
group 2 n/N 
(%) 
Control 
group n/N 
(%) 
Significance test Quality of evidence 
(EPHPP) 
Stein 2016 Biochemically 
confirmed 
smoking 
cessation 
 
12 Carbon monoxide-confirmed 
abstinence (expired breath scores <8 
parts per million) in persons who self-
reported abstinence in the 7 days 
immediately prior to assessment 
 
Week 7 
 
 
1/12 (8.3%)    Weak 
Week 9 0/12 (0.0%) 
Caponnetto 
2013 
Self-report and 
biochemically 
verified 
abstinence 
from tobacco 
14 (12) Complete self-reported abstinence 
from tobacco smoking (not even a 
puff) for the 30 day period prior to 
assessment plus eCO concentration 
≤10 ppm 
52 weeks 2/14 (14.3%)  
 
 
  Weak 
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smoking   
 
 
Pratt 2016 Smoking 
abstinence. 
21 Self-reported smoking abstinence in 
the week prior to assessment 
 
4 weeks 2/21 (9.5%)    Weak 
 
 
CO levels ≤4 ppm 
 
4 weeks 2/21 (9.5%) 
Both of the above criteria met 4 weeks 1/21 (4.8%) 
OBSERVATIONAL STUDIES         
Study ID Outcome Total participants 
(retained at last 
follow up) 
Method of outcome assessment Time of 
follow up 
E-cigarette 
users (%) 
Non-e-
cigarette 
users (%) 
 Significance test Quality of evidence 
(EPHPP) 
Prochaska 
2014 
Tobacco 
abstinence 
956 Unclear 18 months 21% 19%  X2=0.12, p=.726 Weak 
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Table 2. Summary of quantitative findings for smoking reduction 
 
SMOKING REDUCTION – DATA FROM SECONDARY ANALYIS OF AN RCT     
Study ID Outcome Total 
participants 
Time of 
follow up 
Intervention 
group 1 (SD) 
Intervention 
group 2 (SD) 
Control group 
(SD) 
Significance test Quality of 
evidence 
O’Brien 
2015 
Mean reduction in cigarettes smoked per day 
(among those who did not quit) from baseline 
to follow up 
86 26 weeks 9.9 (7) 4.7 (3.5) 5.7 (6.3) 0.035 (patch vs. 16 mg e-cig) 
0.068 (16 mg vs. 0 mg e-cig) 
0.083 (patch vs. combined e-cig 
Moderate 
Percentage reduction in cigarettes smoked per 
day (among those who did not quit) 
86 26 weeks 49% (30%) 31% (30%) 29% (30%) 0.025 (patch vs. 16 mg e-cig) 
0.153 (16 mg vs. 0 mg e-cig) 
0.049 (patch vs. combined e-cig) 
Moderate 
SMOKING REDUCTION IN UNCONTROLLED BEFORE AND AFTER STUDIES 
Outcome Study ID Total participants Mean (SD) at baseline Time of follow up Mean (SD) at 
follow up 
Mean reduction Significance test Quality of 
evidence 
Cigarettes per day Stein 2016 
 
 
12 17.8 (5.3) Week 3 
Week 5 
Week 7 
Week 9 
5.4* 
3.0* 
3.9* 
7.0* 
-12.4 (95% CI -15.0 to -9.9) 
-14.8 (95% CI -17.4 to -12.2) 
-13.9 (95% CI -16.6 to -11.2) 
-10.8 (95% CI -13.4 to -8.2) 
P<0.001 
P<0.001 
 
P<0.001 
Weak 
Caponnetto 
2013 
14 19† 
 
52 weeks 
 
13† 
 
-6* 
 
NR Weak 
Pratt 2016‡ 
 
21 27 4 weeks 10 -17 NR Weak 
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eCO Caponnetto 
2013 
14 25† 52 weeks 15† -10* NR Weak 
Pratt 2016 21 27.37ppm (16.9) 4 weeks 15.21ppm (9.2) -12.16* P=0.004 Weak 
Cigarettes per week 
 
Pratt 2016 
 
21 191.9 (159.3) 4 weeks 
 
66.7 (76.3) -125.2* P=0.005 Weak 
OBSERVATIONAL PROSPECTIVE COHORT STUDY 
Study ID Outcome Method of outcome 
assessment 
Time of follow up E-cigarette users 
mean reduction 
Non-e-cigarette users mean reduction Significance test Quality of 
evidence 
Prochaska 2014 Smoking 
reduction 
Self-report reduction 
in cigarettes per day 
 
18 months -7.1 (SD 12.5) -6.6 (SD 11.0) F(1,703)=.12, p=.730 Weak 
Self-report cigarettes 
per day 
 
18 months 10 (8.9) 10.1 (9.0) F(1,710)=.01, 
p=50.915). 
 
≥50% reduction 18 months 51% 51% X2=.001, p=.978.  
*Calculated for the purposes of this review 
† Data extracted from a graph 
‡ Self-reported weekly tobacco use divided by 7 to provide comparable measure 
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 Figure 1. Study flow diagram for systematic review of the effectiveness of e-
cigarettes for vulnerable groups (56) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 2627 records identified through database 
searching: 
MEDLINE via Ovid SP (n= 294) 
EMBASE via Ovid SP (n= 894) 
PsychINFO via EBSCOhost (n= 96) 
CINAHL via EBSCOhost (n =763) 
ASSIA (n =171) 
ProQuest Dissertation and Theses (n =404) 
OpenGrey (n =5) 
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1 additional record identified 
through other sources 
2025 records after duplicates removed 
2025 records screened 1979 records excluded 
 46 full-text articles 
assessed for eligibility 
 Full text articles excluded:  
 
- Study design  
(n=30) 
- Population (n=4) 
- Intervention (n=1) 
- No data on review 
primary or 
secondary 
outcomes (n=1) 
 9 studies included 
(reported in 9 articles and 
a conference abstract) 
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Figure 2. Analytical themes mapped to the COM-B model of behaviour change (note some themes are mapped to more than one 
component) 
 
Physical capability Psychological capability Physical opportunity Social opportunity Automatic motivation Reflective motivation 
 
A) Design 
 
D) Motivation for harm reduction F) Combustible cigarette bans 
 
H) Social connectedness and 
support 
J) Design L) Continued or worsening addiction/habit 
B) Practical 
barriers 
E) Motivation for smoking cessation G) Cost I) Reversing de-normalisation 
of tobacco use 
K) Physical side effects M) Design 
 
C) Safety     N) Effect on psychiatric symptoms and 
medication side effects 
     O) Empowerment 
     P) Hobby/habit/distraction 
     Q) Preferred to NRT/pharmacotherapy 
     R) Social connectedness and support 
      
 
          Barriers           Facilitators            Act as both barriers and facilitators 
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